PBIO Flashcards
Type 0:
A. GSD 0
B. Andersen disease
C. Tarui disease
A. GSD 0
Type 1:
A. Forbes-Cori disease
B. Hers disease
C. Von Gierke
C. Von Gierke
Type 2:
A. Forbes-Cori disease
(rare)
B. Pompe disease
(serios type of GSD)
C. Andersen disease
B. Pompe disease
(serios type of GSD)
Type 3:
A. Forbes-Cori disease
(rare)
B. McArdle disease
C. Andersen disease
A. Forbes-Cori disease
(rare)
Type 4:
A. Tarui disease
B. McArdle disease
C. Andersen disease
C. Andersen disease
Type 5:
A. GSD 0
B. Forbes-Cori disease
(rare)
C. McArdle disease
C. McArdle disease
Type 6
A. GSD 0
B. Hers disease
C. McArdle disease
B. Hers disease
Type 7
A. Pompe disease
B. Von Glerke
C. Tarui disease
C. Tarui disease
Deficiency of GSD 0
A. Glycogen synthase
B. Myophosphorylase
C. Debranching enzyme
A. Glycogen synthase
Deficiency of Von Gierke
A. Glycogen synthase
B. Myophosphorylase
C. Glucose 6-phosphate
C. Glucose 6-phosphate
Deficiency of Pompe disease
A. Phosphprylase (necessary to
breakdown glycogen)
B. Acid maltase enzyme
C. Transglucosidase (glucosyl
transferase enzyme)
B. Acid maltase enzyme
Deficiency of Forbes Cori disease
A. Debranching enzyme
B. Acid maltase enzyme
C. Transglucosidase (glucosyl
transferase enzyme)
A. Debranching enzyme
Deficiency of Andersen disease
A. Debranching enzyme
B. Myophosphorylase
C. Transglucosidase (glucosyl
transferase enzyme)
C. Transglucosidase (glucosyl
transferase enzyme)
Deficiency of McArdle disease
A. Phosphofructokinase
B. Myophosphorylase
C. Phosphprylase (necessary to
breakdown glycogen)
B. Myophosphorylase
Deficiency of Hers diseases
A. Phosphofructokinase
B. Myophosphorylase
C. Phosphprylase (necessary to
breakdown glycogen)
C. Phosphprylase (necessary to
breakdown glycogen)
Deficiency of Tarui disease
A. phosphofructokinase
B. Acid maltase enzyme
C. Glycogen synthase
A. phosphofructokinase
Clinical features of GSD 0
A. Muscle damage
B. Muscle cramps
D. Liver damage
B. Muscle cramps
Clinical features of Von Gierke
A. Liver damage
B. Cardiac damage
C. Muscle damage
A. Liver damage
Clinical features of Pompe disease
A. Muscle cramps
B. Liver damage
C. Cardiac damage
C. Cardiac damage
Clinical features of Forbes Cori disease
A. Muscle damage
B. Cardiac damage
C. Liver damage
C. Liver damage
Clinical features of Andersen disease
A. Liver damage
B. Muscle crams
C. SOB
A. Liver damage
Clinical features of McArdle disease
A. Liver damage
B. Muscle damage
C. Muscle cramps
B. Muscle damage
Clinical features of Hers disease
A. Muscle cramps
B. Muscle damage
C. Liver damage
C. Liver damage
Clinical features of Tarui disease
A. Cardiac damage
B. Muscle damage
C. Liver damage
B. Muscle damage
Manifestation of GSD 0
A. Fasting hypoglycemia
B. Extreme enlargement of liver
(accumulation of glycogen)
C. Muscle fatigue, Muscle pain
A. Fasting hypoglycemia
Manifestation of Von Gierke
A. Fasting hypoglycemia
B. Exercise induce cramps
C. Hepatomegaly, platelet dysfunction and growth retardation
C. Hepatomegaly, platelet dysfunction and growth retardation
Manifestation of Pompe disease
A. IIA- infantile form, IIB- juvenile, IIC- adult
B. Lysosomal storage disease (accumulation of glycogen in
lysosome)
C. General: skeletal muscle
weakness
D. All the above
D. All the above
Manifestation of Forbes Cori disease (rare)
I. Hepatomegaly, hypoglycemia
and myopathy
II. Can lead to death within 5 years
of age
III. Affects liver, heart, skeletal
muscle
A. I only
B. II only
C. I and III
C. I and III
Manifestation of Andersen Disease
I. Rare inherited condition that
causes severe muscle pain and
cramps
II. Abnormal glycogen in liver and
muscle
III. Can lead to death within 5 years
of age
A. I and II
B. II and III
C. II only
B. II and III
Manifestation of McArdle disease
I. Rare inherited condition that
causes severe muscle pain and
cramps
II. Exercise induce cramps
III. Rhabdomyolysis
A. I only
B. II and III
C. I, II, and III
C. I, II, and III
Manifestation of Hers disease
I. Lysosomal storage disease
(accumulation of glycogen in
lysosome)
II. Extreme enlargement of liver
(accumulation of glycogen)
III. Abnormal glycogen in liver and
muscle
A. I only
B. II only
C. I, II, and III
B. II only
Manifestation of Tarui disease
A. Muscle fatigue and Muscle pain
B. Fasting hypoglycemia
C. Hepatomegaly, hypoglycemia
and myopathy
A. Muscle fatigue and Muscle pain
Site of Cyanide
A. Cytochrome oxidase
B. ADP phosphorylation
C. NADH-CoQ reductase
A. Cytochrome oxidase
Effect of Cyanide
A. All intermediates before and including cyt a will be in the reduced state; all intermediates after and including cyt c1 will be oxidized states. Blocks site lll
B. Blocks transfer of electrons to O2. Blocks at site IV
C. Inhibits entry of ADP into mitochondria and ATP export. Stop electron transport because of lack of ADP. Inside, all ADP is converted to ATP
B. Blocks transfer of electrons to O2. Blocks at site IV
Site of Antimycin
A. ADP phosphorylation
B. ADP-ATP transporter
C. Electron transfer from cyt b to cyt c1
C. Electron transfer from cyt b to cyt c1
Effect of Antimycin
A. All intermediates before and including cyt a will be in the reduced state; all intermediates after and including cyt c1 will be oxidized
B. Blocks phosphorylation of ADP. Does not inhibit uncouples oxidations
C. Blocks oxidation of NADH (site l). NADH will be reduced; Substrates such as succinate that enter via FADH will still be oxidized and make 2 ATPs/mol
A. All intermediates before and including cyt a will be in the reduced state; all intermediates after and including cyt c1 will be oxidized
Site of Rotenone
A. Cytochrome oxidase
B. NADH-CoQ Reductase
C. Electron transfer from cyt b to cyt c1
B. NADH-Co2 Redutase
Effect of Rotenone
A. Blocks transfer of electrons to O2. Blocks at site IV
B. Blocks phosphorylation of ADP. Does not inhibit uncouples oxidations
C. Blocks oxidation of NADH (site l). NADH will be reduced; Substrates such as succinate that enter via FADH will still be oxidized and make 2 ATPs/mol
C. Blocks oxidation of NADH (site l). NADH will be reduced; Substrates such as succinate that enter via FADH will still be oxidized and make 2 ATPs/mol
Site of Oligomycin
A. ADP Phosphorylation
B. NADH-CoQ Reductase
C. Cytochrome oxidase
A. ADP phosphorylation
Effect of Oligomycin
A. Blocks transfer of electrons to O2. Blocks at site IV
B. Inhibits entry of ADP into mitochondria and ATP export. Stop electron transport because of lack of ADP. Inside, all ADP is converted to ATP
C. Blocks phosphorylation of ADP. Does not inhibit uncouples oxidations
C. Blocks phosphorylation of ADP. Does not inhibit uncouples oxidations
Site of Atractyloside and bongkrekate
A. NADH-CoQ Reductase
B. Electron transfer from cyt b to cyt c1
C. ADP-ATP transporter
B. ADP-ATP transporter
Effect of Atractyloside and bongkrekate
A. Blocks phosphorylation of ADP. Does not inhibit uncouples oxidations
B. Inhibits entry of ADP into mitochondria and ATP export. Stop electron transport because of lack of ADP. Inside, all ADP is converted to ATP
C. All intermediates before and including cyt a will be in the reduced state; all intermediates after and including cyt c1 will be oxidized
B. Inhibits entry of ADP into mitochondria and ATP export. Stop electron transport because of lack of ADP. Inside, all ADP is converted to ATP